Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

diluted, compared to a net income of $0.29 per share, basic, and $0.25 per share, diluted, for the same period in 2007. Net income per share for the year ended December 31, 2008 was $0.95 per share, basic, and $0.83 per share, diluted, compared to net income of $1.37 per share, basic, and $1.21 per share, diluted, for the same period in 2007.

The primary drivers of the decrease in net income for the fourth quarter and year ended December 31, 2008 were the increase in R&D, SG&A and intangible amortization expenses, and lower interest income offset by the lower tax expense. Additionally, in the fourth quarter of 2008 we had a $2.3 million charge to write down to fair value our previous corporate headquarters which is currently held for sale.

Operating Highlights

During the three months and year ended December 31, 2008, net sales increased 4.9 percent and 14.0 percent, respectively, compared to the same periods in 2007.

The cost of sales for the three months and year ended December 31, 2008 increased $0.1 million and remained consistent, respectively, as compared to the same periods in 2007. For the three months and year ended December 31, 2008 the cost of sales was $2.1 million and $8.9 million, respectively, compared to $2.0 million and $8.9, respectively, for the same period in 2007.

Investment in our product pipeline and the company continued to grow as research and development (R&D) and selling, general and administrative (SG&A) expenses in the fourth quarter and year ended December 31, 2008 were $43.6 million and $131.7 million, respectively compared to $25.2 million and $72.9 million for the fourth quarter and year ended December 31, 2007, respectively. The quarter increases were due primarily to our investments in our infrastructure related to our development programs, costs to support the Cinryze open label trial and launch related costs, an
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 Tabletop SEMs are ... SEMs but have limited performance and capability such as ... size SEMs would normally provide better imaging performance and ... operate and have a higher cost of maintenance. ... gap between these two types of SEM product, offering ...
(Date:6/18/2013)... HONG KONG, June 18, 2013 China Cord ... the "Company"), China,s leading provider of cord blood collection, ... storage services, today announced its preliminary unaudited financial results ... year 2013 ended March 31, 2013. ... for the fourth quarter of fiscal 2013 increased by ...
(Date:6/18/2013)... Angeles, CA (PRWEB) June 18, 2013 (PRWEB) June ... construction’s #1 time and attendance system in North ... software that shares employee data and payroll records ... AccountLinx Plus automates ExakTime software setup ... The software imports employee data from a business’ ...
(Date:6/18/2013)... Demanding industrial and environmental conditions are ... Sapphire and Glass Ball Lenses, now available in an ... Company , of Philadelphia , PA. , Optical Ball ... light beams without the need for direct physical contact. ... (9 mohs) make it the ideal choice for fiber-optic ...
Breaking Biology Technology:Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13ExakTime Introduces AccountLinx Plus 2Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2
... BAX ) announced today that its Board of ... of the company,s,common stock to be executed upon completion ... less than $700 million of remaining authorization under its,previous ... March,2007. Shares will be repurchased in the open market ...
... 18 /PRNewswire/ - Aegera Therapeutics announced today,the ... trial for AEG33773, a,novel, orally bioavailable small ... diabetic neuropathy. The Phase I study will ... AEG33773 using a randomized,double blind, placebo controlled, ...
... siRNA Targeting of, VEGF Expression, Further Strengthening OPKO,s RNAi Intellectual Property ... ... OPKO Health, Inc. (Amex: OPK ),today announced that it has been ... for methods related to the use and,administration of small interfering RNAs (siRNAs) ...
Cached Biology Technology:Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion 2Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 2OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 3OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 4
(Date:6/19/2013)... new variety of canary seeds bred specifically for human ... ideal for people with celiac disease (CD), scientists have ... of Agricultural and Food Chemistry . , Joyce ... 3 million people in the United States alone have ... wheat, barley, rye and other grains that contain gluten-related ...
(Date:6/19/2013)... A Cornell University study offers further proof that the ... 6 million years ago was profoundly influenced by mutations ... on and off. , The study, published June 9 ... 40-year-old hypothesis that regulation of genes must play an ... between humans and chimps in the proteins produced by ...
(Date:6/19/2013)... 2013 Elsevier, a world-leading provider of scientific, technical ... announce the launch of a new open access journal, ... GeoResJ , Elsevier,s earth and planetary science journals ... journal aims to provide a forum for rapid publication ... The journal will be co-edited by six Executive Editors, ...
Breaking Biology News(10 mins):New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3
... genetic diversity in crops is traditional practice for agriculture ... develop breeding programs with great care for the security ... numerous risks the world,s food supplies face with the ... essential as an insurance against unforeseeable changes in the ...
... -- A Duke University-led team has brought powerful software ... Working together, computer scientists and biochemists have developed and ... to change the machinery that bacteria use to make ... set of computer rules known as the algorithm "K*" ...
... distinguishes itself as the fastest growing greenhouse gas in ... emissions depends on our ability to measure the increase ... increase. Until the late 1950s when high ... whether the industrial revolution and the associated increase in ...
Cached Biology News:Identifying mega-targets for high-yield plant breeding 2Duke software dramatically speeds enzyme design 2Duke software dramatically speeds enzyme design 3Carbon accounting from atmospheric measurements -- the aircraft perspective 2
... ideal for use as source plates for arraying ... to 5µl). These plates are available either with ... Features 384 round wells Cylindrical ... volume (cylindrical well), 55µl well volume (V well) ...
... Reagent A - Fixation medium Reagent B ... intended for fixing cells in suspension with ... with Reagent B. This procedure gives antibodies ... morphological scatter characteristics of the cells intact. ...
... Rabbit polyclonal to JNK1 (phospho T183 + Y185) ... internal domain containing phosphorylated T183/Y185. Reactivity / ... Not yet tested in other species. Background ... including the ERK, JNK, and p38 kinases. The ...
... Dako Target Retrieval Solution, pH 9 (x ... buffer, pH 9, intended for heat-induced target ... is well-suited for use on formalin-fixed, paraffin-embedded ... with 0.01 mol/L citrate buffer, pH 6, ...
Biology Products: